Market Introduction
The pharmaceutical fill and finish outsourcing are more inclined towards contract manufacturing. There are several types of contract manufacturing for pharmaceuticals as well as for biotechnology products that involve partial contract manufacturing and complete manufacturing of pharmaceuticals and biotechnology products.
Moreover, the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars is driving the market’s growth. However, complex processes and high cost of production critically impacts the growth of the market.
The COVID-19 pandemic has brought unprecedented challenges globally. Similar effects were witnessed on Asia-Pacific Biopharmaceutical industry that has been disturbed for few months of 2020 during the outbreak of the COVID-19 pandemic. However, with the rising demand for products to treat the COVID-19 infection, the biopharmaceutical and pharmaceutical companies in the countries such as India and China have increased their production of APIs as the countries are the largest exporters to western companies. For instance, Wockhardt Ltd is in talks with the Indian government to offer its fill-finish capacity for the covid-19 vaccines that will be developed in the country, as well as with some firms whose vaccines are currently in phase I/II trials globally. Moreover, on 07 May 2020, Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services with sites in Belgium, United States, Japan, and India, announced it has entered into a manufacturing services agreement with CytoDyn Inc., a late-stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients.
Market Overview and Dynamics
The Asia Pacific pharmaceutical fill and finish outsourcing market is expected to reach US$ 691.8 million by 2028 from US$ 410.0 million in 2021. The market is estimated to grow at a CAGR of 7.8% from 2021–2028. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Currently, over 115 companies are actively providing services for the fill finish of biologics. Many service providers have also acquired other players in the recent past to enhance their service offerings. For instance, Sanofi has outsourced the manufacturing of its biologics to Boehringer Ingelheim. Moreover, AbbVie operations have successfully developed and delivered drug products for more than 130 years; over 14 million small-volume parenteral (SVPs) are filled annually across AbbVie’s network, and the filled products are distributed over 175 countries.
Key Market Segments
In terms of state of finished products, the liquid segment accounted for the largest share of the Asia Pacific pharmaceutical fill and finish outsourcing market in 2020. In terms of content, the organic substances isolated from microorganism’s segment accounted for the largest share of the Asia Pacific pharmaceutical fill and finish outsourcing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the pharmaceutical fill and finish outsourcing market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., WOCKHARDT, Cytovance Biologics, MabPlex International Ltd, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH.
Reasons to Buy Report
ASIA PACIFIC PHARMACEUTICAL FILL AND FINISH OUTSOURCING MARKET SEGMENTATION
By State of Finished Product
• Solids
• Semi-Liquid
• Liquid
By Content
• Organic Substances Isolated from Animal Origin
• Organic Substances Isolated from Microorganisms
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 410.0 Million |
| Market Size by 2028 | US$ 691.8 Million |
| CAGR (2021 - 2028) | 7.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By State of Finished Product
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market is valued at US$ 410.0 Million in 2021, it is projected to reach US$ 691.8 Million by 2028.
As per our report Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market, the market size is valued at US$ 410.0 Million in 2021, projecting it to reach US$ 691.8 Million by 2028. This translates to a CAGR of approximately 7.8% during the forecast period.
The Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market report:
The Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market
